

31 May 2018

CardieX Limited

(Previously AtCor Medical Holdings Limited)

Revised Timing on Trade Under New Ticker Code

Further to announcement made yesterday, CardieX Limited (ASX:ACG, the Company), announced that following shareholder approval obtained on 28 May 2018, the Company's name has officially changed with the Australian Securities Investment Commission to **CardieX Limited**.

The change to the ASX listing code from "ACG" to "CDX" has however been delayed by the ASX as a result of the current entitlements issue that is underway. To avoid confusion in the quotation of those securities the ASX has revised its date of commencement of trade to be after the conclusion of that issue.

The new date for commencement of trade under ticker code "**CDX**" will be Monday **18 June 2018**, before which trade will continue under the existing ticker code.

About CardieX

CardieX is a global health technology company focused on developing solutions for large-scale population health disorders. The Company's "AtCor Medical" division develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease.

For more information please contact:

Chief Executive Officer Craig Cooper Ph: +61 429 993 399 ccooper@cardiex.com

Chief Financial Officer Jarrod White Ph: +61 2 8296 0000 jwhite@cardiex.com Investor Relations Peter Taylor Ph: +61 412 036 231 peter@nwrcommunications.com.au